STOCK TITAN

SRX Global (NYSE: SRXH) closes $3.472M Series B and warrant financing

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

SRX Global Inc. reported an additional private placement closing under a Securities Purchase Agreement originally dated March 16, 2026. The agreement permits the sale of up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million, together with accompanying warrants.

At the initial March 16, 2026 closing, the company sold 5,660 Series B shares and 22,237,666 warrants for cash proceeds of approximately $4.528 million. On July 27, 2026, at an Additional Closing, it sold 4,340 Series B shares and 284,156 warrants for approximately $3.472 million in cash, with the warrant number reflecting a 60-for-1 reverse stock split effective July 2, 2026.

The securities were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. These securities are restricted and may not be offered or sold in the United States absent registration or an applicable exemption.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Private placement capacity $8.0 million Aggregate purchase price available under Securities Purchase Agreement
Series B shares allowed 10,000 shares Maximum Series B convertible preferred stock under agreement
Initial closing proceeds $4.528 million Cash received March 16, 2026 for Series B and warrants
Initial warrants issued 22,237,666 warrants Warrants to purchase common stock issued at initial closing
Additional closing proceeds $3.472 million Cash received July 27, 2026 for Series B and warrants
Additional Series B shares 4,340 shares Series B preferred issued at Additional Closing
Additional warrants issued 284,156 warrants Adjusted for 60-for-1 reverse stock split effective July 2, 2026
Reverse stock split ratio 60-for-1 Reverse stock split effective July 2, 2026 impacting warrant count
Securities Purchase Agreement financial
"entered into a Securities Purchase Agreement with certain accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Series B convertible preferred stock financial
"up to 10,000 shares of the Company’s Series B convertible preferred stock"
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
reverse stock split financial
"adjusted to reflect the Company’s previously announced 60-for-1 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Section 4(a)(2) regulatory
"exemption from registration provided by Section 4(a)(2) of the Securities Act"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506 of Regulation D regulatory
"and/or Rule 506 of Regulation D promulgated thereunder"
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did SRXH announce regarding its July 27, 2026 private placement?

SRX Global Inc. completed an Additional Closing on July 27, 2026, selling 4,340 Series B preferred shares and 284,156 warrants for approximately $3.472 million in cash. The warrants reflect the company’s 60-for-1 reverse stock split effective July 2, 2026.

What is the total capacity of SRXH’s Securities Purchase Agreement?

The Securities Purchase Agreement allows investors to buy up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million, together with accompanying warrants. These sales may occur in one or more closings with accredited investors.

What were the terms of SRXH’s initial March 16, 2026 closing?

On March 16, 2026, SRX Global sold 5,660 shares of Series B preferred stock and 22,237,666 warrants in a private placement, receiving approximately $4.528 million in cash proceeds. This transaction occurred under the same Securities Purchase Agreement with certain accredited investors.

How did SRXH’s reverse stock split affect the warrants in the Additional Closing?

The company stated that the 284,156 warrants issued at the Additional Closing were adjusted for its previously announced 60-for-1 reverse stock split, which took effect on July 2, 2026. This adjustment changed the warrant count compared with the larger pre-split warrant issuance in March.

Under what exemptions were SRXH’s securities issued in these private placements?

SRX Global relied on exemptions from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The company cited investor representations in the Securities Purchase Agreement and noted that the securities are restricted and cannot be sold without registration or a valid exemption.

Are SRXH’s newly issued securities freely tradable in the United States?

No. SRX Global stated that the securities issued in these private placements were not registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements, consistent with Section 4(a)(2) and Rule 506.
false 0001471727 0001471727 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 27, 2026

 

 

 

SRX Global Inc.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-40477   83-4284557

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

801 US Highway 1

North Palm Beach, Florida 33408

(Address of Principal Executive Offices) (Zip Code)

 

 

 

(Registrant’s Telephone Number, Including Area Code): (212) 896-1254

 

N/A

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value share   SRXH   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

Private Placement

 

Additional Closing under Securities Purchase Agreement

 

As previously announced, on March 16, 2026, SRX Global Inc. (f/k/a SRx Health Solutions, Inc.), a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein (the “Investors”). Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”) and accompanying warrants (“Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) may be purchased for an aggregate purchase price of up to $8.0 million in one or more closings.

 

As previously announced, on March 16, 2026 at the initial closing, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain Investors purchased, in a private placement: 5,660 shares of the Series B Preferred Stock and 22,237,666 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $4.528 million, paid in cash.

 

Pursuant to the Securities Purchase Agreement, the Investors have the right, severally, subject to the satisfaction of certain conditions, to require the Company to participate in one or more additional closings for the purchase of up to an aggregate of 4,340 additional shares of Series B Preferred Stock and Warrants (each such transaction, an “Additional Closing”).

 

On July 27, 2026, at an Additional Closing pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement: 4,340 shares of the Series B Preferred Stock and 284,156 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $3.472 million, paid in cash. Such number of Warrants is adjusted to reflect the Company’s previously announced 60-for-1 reverse stock split, which took effect July 2, 2026.

 

All such securities will not be registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws. The Company relied on this exemption from registration in entering into the Securities Purchase Agreement and the Company will rely upon this exemption from registration in issuing such securities based in part on representations made by the investors in the Securities Purchase Agreement. The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described herein.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 28, 2026 SRX GLOBAL INC.
     
  By: /s/ Carolina Martinez
  Name: Carolina Martinez
  Title: Chief Executive Officer

 

 

 

 

Filing Exhibits & Attachments

3 documents